3 completed, 3 terminated, 2 recruiting, 1 active not recruiting. 5 Phase 1, 5 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Terminated 1 |
| Not applicable | 1 | Terminated 1 |
Follow Fallopian Tube Carcinosarcoma: new trials by email Literature Review of Fallopian Tube Carcinosarcoma trials Research Report on Fallopian Tube Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial Biopsy, Biospecimen Collection, Computed Tomography - Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 78 | 2024-11-12 | 2026-10-02 |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer Pamiparib, Surufatinib - Ovarian Cancer, Ovarian Carcinoma | Phase 1 / Phase 2 | Completed | Sun Yat-sen University | 29 | 2022-09-22 | 2026-03-10 |
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Entinostat, Olaparib - Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2020-10-01 | 2022-04-04 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 431 | 2009-10-28 | 2021-10-20 |
Ovarian Neoplasms (7) · Fallopian Tube Neoplasms (5) · Brenner Tumor (2) · Endometrial Neoplasms (1)
Adnexal Diseases (7) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genital Diseases (7) · Genital Diseases, Female (7) · Genital Neoplasms, Female (7) · Gonadal Disorders (7) · Neoplasms (7) · Neoplasms by Site (7) · Ovarian Diseases (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7) · Fallopian Tube Diseases (5)
Bevacizumab (4) · Disulfides (4) · Immunoglobulin G (4) · Biopsy (3) · Specimen Handling (3) · Taxes (3) · Magnetic Resonance Spectroscopy (2) · Paclitaxel (2) · pembrolizumab (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Adenosine Diphosphate Ribose (1) · Albumin-Bound Paclitaxel (1) · Blood Component Removal (1) · Carboplatin (1)
Mayo Clinic (4) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · Sun Yat-sen University (1) · University of Washington (1) · Vanderbilt-Ingram Cancer Center (1)
United States (8) · China (1)
Matthew S. Block, MD, PhD (2) · Emese Zsiros (1) · Evanthia Galanis, M.D. (1) · Katherine M Bell-McGuinn (1) · Kathryn Pennington (1) · Marta Crispens, MD (1) · Matthew S. Block, M.D., Ph.D. (1)
R01CA267690 (1), R01CA276313 (1), R21CA215662 (1), U10CA027469 (1), U10CA180868 (1)